CTSO CytoSorbents Corporation

0.06 (3.23%)
After Hours
Last Updated: 16:58:44
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 106,961
Bid Price 1.83
Ask Price 2.06
News (2)
Day High 1.99


52 Week Range


Day Low 1.83
Company Name Stock Ticker Symbol Market Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 3.23% 1.92 16:58:44
Open Price Low Price High Price Close Price Prev Close
1.88 1.83 1.99 1.92 1.86
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
831 106,961 $ 1.89 $ 202,076 - 1.03 - 4.59
Last Trade Time Type Quantity Stock Price Currency
16:40:52 20 $ 1.97 USD

CytoSorbents Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
85.18M 44.36M - 34.69M -32.81M -0.74 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytoSorbents News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CTSO Message Board. Create One! See More Posts on CTSO Message Board See More Message Board Posts

Historical CTSO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.072.07471.831.9743,593-0.15-7.25%
1 Month2.482.6651.832.1571,470-0.56-22.58%
3 Months3.494.291.833.0269,680-1.57-44.99%
6 Months3.514.291.833.0762,947-1.59-45.3%
1 Year1.194.591.032.43102,6560.7361.34%
3 Years7.9211.6841.035.71204,892-6.00-75.76%
5 Years13.5013.891.036.71264,556-11.58-85.78%

CytoSorbents Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.